Article Correctness Is Author's Responsibility: FDA to Review Lumateperone for Treatment of Schizophrenia

The article below may contain offensive and/or incorrect content.

Lumateperone and follow-on compounds are also being evaluated for bipolar depression, behavioral disturbance associated with dementia, sleep disturbances associated with neuropsychiatric disorders, and other neuropsychiatric conditions including major depressive disorder and autism.